Skip to content
Sign in
StableHealthReported 2026-11-13 02:00

PAI Pharma Acquires Nexus Pharmaceuticals, Expanding Portfolio of Sterile Injectable Products

PAI Pharma acquired Nexus Pharmaceuticals, adding over 20 hospital injectable products to its portfolio and expanding its presence in sterile injectable and hospital-focused pharmaceutical markets.

In depthRead the in-depth story

Why it matters. PAI Pharma and Nexus Pharmaceuticals are strengthening their offerings in critical care and oncology, potentially improving patient access to essential medicines.

01

Who and what it touches

Nexus Pharmaceuticals…acquiresOlympus Partnerspart ofOral liquid medicinesmanufacturesSterile and ready-to-…manufacturesPAI Pharma

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-13 02:00
    PAI Pharma ("PAI"), a portfolio company of Olympus Partners, and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines, and Ready-To-Use ("RTU") sterile injectable and hospital-focused products, today announced the acquisition of Nexus Pharmaceuticals, LL…
    View source